Irena Klima

Bern, BE, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

CRIPTO's multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data.

CRIPTO's multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data.

Journal: Oncogene

Published: April 29, 2024

Prediction of Biochemical Recurrence Based on Molecular Detection of Lymph Node Metastasis After Radical Prostatectomy.

Prediction of Biochemical Recurrence Based on Molecular Detection of Lymph Node Metastasis After Radical Prostatectomy.

Journal: European urology open science

Published: July 21, 2022

Bladder cancer organoids as a functional system to model different disease stages and therapy response.

Bladder cancer organoids as a functional system to model different disease stages and therapy response.

Journal: Nature communications

Published: June 14, 2022

Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity.

Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity.

Journal: Frontiers in oncology

Published: January 07, 2021

Stroma Transcriptomic and Proteomic Profile of Prostate Cancer Metastasis Xenograft Models Reveals Prognostic Value of Stroma Signatures.

Stroma Transcriptomic and Proteomic Profile of Prostate Cancer Metastasis Xenograft Models Reveals Prognostic Value of Stroma Signatures.

Journal: Cancers

Published: December 01, 2020

Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity.

Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity.

Journal: Frontiers in oncology

Published: January 30, 2020

Patient-derived xenografts and organoids model therapy response in prostate cancer.

Patient-derived xenografts and organoids model therapy response in prostate cancer.

Journal: Nature communications

Published: January 15, 2020

miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo.

miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo.

Journal: BMC cancer

Published: January 25, 2019

Therapeutic Targeting of CD146/MCAM Reduces Bone Metastasis in Prostate Cancer.

Therapeutic Targeting of CD146/MCAM Reduces Bone Metastasis in Prostate Cancer.

Journal: Molecular cancer research : MCR

Published: November 14, 2018

CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.

CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.

Journal: The Journal of pathology

Published: November 20, 2017

ALK1Fc Suppresses the Human Prostate Cancer Growth in in Vitro and in Vivo Preclinical Models.

ALK1Fc Suppresses the Human Prostate Cancer Growth in in Vitro and in Vivo Preclinical Models.

Journal: Frontiers in cell and developmental biology

Published: May 31, 2017

Showing 1-11 of 11

Last Updated: 09/26/2026